ARKG vs SQQQ
ARK Genomic Revolution ETF vs ProShares UltraPro Short QQQ
ARKG$30.38
ARK Genomic Revolution ETF
Companies advancing genomics and molecular biology.
Expense: 0.75%Yield: 0.00%
SQQQ$45.73
ProShares UltraPro Short QQQ
3x inverse daily performance of the Nasdaq-100.
Expense: 0.95%Yield: 8.99%
Quick take
- • ARKG has the lower expense ratio at 0.75% vs 0.95% for SQQQ.
- • SQQQ pays a higher dividend yield (8.99%).
Side-by-side metrics
| Metric | ARKG | SQQQ |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.95% |
Dividend yield Trailing 12-month yield. | 0.00% | 8.99% |
AUM Assets under management — bigger funds are typically more liquid. | $1.24B | $2.91B |
YTD return | 7.21% | -32.89% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.35 | -3.08 |
P/E ratio | — | — |
Last price | $30.38 | $45.73 |
Inception | — | — |
Issuer | ARK | ProShares |
ARKG top holdings
Top holdings · ARKG
| TEM | Tempus AI Inc Class A common stock | 9.45% |
| TWST | Twist Bioscience Corp | 9.02% |
| CRSP | CRISPR Therapeutics AG | 8.94% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 5.78% |
| BEAM | Beam Therapeutics Inc | 5.44% |
| ABSI | Absci Corp | 4.79% |
| NTRA | Natera Inc | 4.08% |
| ILMN | Illumina Inc | 4.04% |
| NTLA | Intellia Therapeutics Inc | 3.83% |
| PSNL | Personalis Inc | 3.59% |
Sector breakdown · ARKG
Healthcare100.0%
SQQQ top holdings
Holdings data unavailable for SQQQ.
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Tempus AI Inc Class A common stock (TEM), which represents 9.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About SQQQ
SQQQ (ProShares UltraPro Short QQQ) is 3x inverse daily performance of the Nasdaq-100. Managed by ProShares, the fund carries $2.9B in assets under management, an expense ratio of 0.95%, a dividend yield of 8.99%.